Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study

Teklehaimanot Fentie Wendie, Getnet Mengistu

Department of Pharmacy, Wollo University, Dessie, Ethiopia

* tkhmnntnt5@gmail.com, Teklehaimanot.fentie@wu.edu.et

Abstract

Background

Although antiretroviral therapy has significantly altered the natural history of human immunodeficiency virus infection and improved the quality of life of patients, there are conflicting reports regarding its impact on hematological outcomes. Thus, this study aimed at investigating the prevalence and predictors of anemia among adults on antiretroviral therapy in Northeast Ethiopia.

Materials and methods

A retrospective cohort study was carried out among adults who began antiretroviral treatment between September 2005 and January 2019 at two governmental hospitals in Dessie town. Data were collected from patients’ medical records using a pretested data extraction instrument. Anemia was the primary outcome variable of the study. It was defined based on WHO criteria after adjustment for altitude and smoking status of measured values. Data were entered and validated using EpiData Version 3.1 and then exported to SPSS Version 20.0 for analysis. Descriptive analysis was done for prevalence and binary logistic regression was carried out to assess whether covariates were associated with experiencing anemia. Statistical significance has been considered at p-value < 0.05.

Results

Medical records of 392 patients (mean age: 35.58 ± 9.46 years) were reviewed. Of the total 392 patients, 218 (55.6%) were females, 261 (66.6%) were categorized under WHO clinical stage III/IV and 134 (34.2%) had a baseline CD4 cell count of <100 cells/mm$^3$. The mean baseline CD4 cell count was 179 cells/mm$^3$ (range: 2 to 853 cells) and 230 (58.7%) of the participants were on zidovudine-based regimen. Anemia was diagnosed among 162 (41.3%) patients. After adjustment for other confounding factors, risk of anemia was significantly associated with low baseline CD4 cell count (AOR 1.80, 95% CI 1.05–3.06) and
Conclusion
In this research, the prevalence of anemia was relatively high. Low baseline CD4 cell count and tenofovir based regimen were independent predictors of anemia; while being educated was found to be protective. Treatment programs should focus on early diagnosis and treatment of HIV as well as routine screening and proper treatment of anemia.

Introduction
The introduction of highly active antiretroviral therapy (HAART) in 1996 and the increasing access to these potent antiretroviral drugs has dramatically improved the rate of HIV disease progression and mortality [1]. However, adverse drug events like hematologic toxicities remain as common causes of morbidity and mortality in people receiving HAART [2, 3]. Anemia is the most commonly reported hematologic abnormality with substantial impact on quality of life and clinical outcomes like HIV disease progression [4–7].

Studies have consistently shown that the prevalence of anemia is high among people living with HIV, particularly among those with advanced disease stage [8, 9]. The prevalence of anemia during the HAART era greatly varies depending on region, clinical settings and threshold used to define anemia [5, 10]. The estimated prevalence of anemia among adults receiving HAART was 35% in Europe and North America [11]; 39.2% in China [12] and 66.7% in Nepal [13]. Other reports also revealed that the prevalence of anemia ranges from 23 to 50% globally and 24 to 58% in Africa [3, 14].

Review of the literature demonstrated high prevalence of anemia among HIV infected adults in Ethiopia with pooled prevalence of 31% [15]. Studies conducted at different times from different parts of the country reported that the prevalence of anemia ranges from 11.4 to 70.1% [16–21]. Accordingly, it was estimated and reported as 23 to 70.1% in Northwest Ethiopia [21]; 36.5 to 53.3% in Southern Ethiopia [17]; 11.4 to 34.6% in Addis Ababa [16, 18, 19]; and 41.2% in Eastern Ethiopia [20].

Anemia in HIV-infected individuals has been associated with reduced quality of life, rapid disease progression, and increased mortality [4, 5, 22–25]. Analysis of a multi-centered data in Europe demonstrated that a 1 g/dL reduction in Hb raised the hazard of death by 57%, after controlling viral load and CD4 lymphocyte count. Accordingly, the latest hemoglobin value was an independent prognostic factor for death [23]. Mortality was higher in the first year following initiation of HAART, with anemia being one of the associated factors suggesting the need for routine screening and treatment of anemia [23, 26]. Anemia has also been associated with rapid progression to AIDS and included in the disease-progression scoring system for patients on HAART [5, 25].

Although HAART has generally been accepted as the gold standard in HIV care [27], there are inconsistent reports regarding its impact on hematological complications [28]. Whereas a number of studies reported that highly active antiretroviral therapy could reduce anemia, others reported no improvement or even anemia as an adverse drug reaction of the antiretroviral therapy [27, 29–34].

Anemia in HIV infection has been reported to be multifactorial being the result of a number of interactive factors making it difficult to determine causality [35, 36]. Antiretroviral and
other drugs are also known to cause anemia [36–38]. Factors often reported to increase risk anemia include ART regimens containing zidovudine, more advanced disease stage or low CD4+ count, nutritional status or body mass index <18.5 kg/M², female sex, duration of HAART, presence of opportunistic infections, and low baseline hemoglobin level [8, 12, 13, 15–18, 21, 30, 39–42].

Previous studies investigated the prevalence and predictors of anemia among HIV infected patients in general. Moreover, its prevalence and predictors vary by setting and population among others. However, there is insufficient data about anemia after initiation of HAART among adults in northeast Ethiopia. Thus, this study aimed at filling this gap by investigating the prevalence and predictors of anemia among adults on HAART.

**Materials and methods**

**Study design, area and period**

A retrospective cohort study was carried out from September 2018 to January 2019 among adults on a standard antiretroviral treatment at ART clinics of Boru Meda and Dessie Referral Hospitals. These are the only governmental hospitals in Dessie town serving majority of clients from the Northeast part of the country. Dessie is located 400 km to the north of the capital Addis Ababa with an altitude between 2,470 and 2,550 meters above sea level. Besides testing and treatment of HIV/AIDS, the hospitals also provide general outpatient and inpatient services including medical, surgical, pediatric, psychiatric, Ophthalmic, Emergency, Gynecology and Obstetrics care.

**Study population and eligibility criteria**

All HIV-positive patients aged 15+ who began ART between September 2005 and January 2018 and were treated for at least 3 months with pre- and post-ART hemoglobin values were eligible for study enrolment. On the other hand, patients who were already anemic at the time of ART initiation, transfer in/out cases, lost to follow up and those with incomplete medical records were excluded.

**Sample size determination and sampling procedure**

Sample size was computed using single population proportion formula based on the following assumptions: true population proportion or estimated prevalence (P) = 0.5, absolute precision (d) = 0.05, and 95% confidence level. Because there was no previous similar study in the area, the true proportion of the population was assumed to be 50%. To account for incomplete medical records, a 2% contingency was added. Thus, the final sample size was 392. Participants were enrolled based on their refill appointment; thus, simple random sampling technique was used.

**Study variables**

Anemia following at least three months of antiretroviral treatment, was the primary outcome variable of the study. Anemia was defined based on WHO criteria as a hemoglobin concentration of <12 g/dl for non-pregnant women and <13 g/dl for men after adjustment for altitude and smoking status of measured values [43]. Accordingly, 0.16 g/dL and 0.13 g/dL were subtracted from measured values for smokers and non-smokers, respectively. It was further classified as mild (11–11.9 g/dl for women and 11–12.9 g/dl for men), moderate (8–10.9 g/dl) and severe (<8 g/dl in both genders). Socio-demographic characteristics (age, gender, educational level), nutritional status, tuberculosis coinfection, WHO clinical stage, baseline CD4 cell
count, ART regimen, adherence, isoniazid and co-trimoxazole preventive therapies were the predictor variables.

Data collection procedure
Socio-demographic characteristics, baseline and follow up clinical and laboratory data, as well as treatment outcomes were extracted from patients’ medical records using a structured and pretested data abstraction format. Unique ART numbers were used for the identification of individual participants. The data abstraction tool has been adopted from ART registry and follow up forms of ART clinics and pretested on transferred-in cases before use. Patient ART registers, follow up medical records and the electronic dispensing database were used as data sources. Laboratory test reports were also used to collect hematologic, virologic and immunologic results. World health organization (WHO) cut off values of hemoglobin were taken after adjustment to altitude and smoking status to define and classify anemia. Study participants were retrospectively followed from the date of enrolment to treatment initiation.

Data quality assurance
Pretest for the applicability of the data collection tool was done and training was given for the data collectors and supervisors before the commencement of the data collection procedure. Data were checked for completeness daily, coded, cleaned and verified before entry.

Data processing and analysis
Data were entered using EpiData Version 3.1 and exported to SPSS Version 20.0 for analysis. Descriptive statistics were used for the analysis of baseline sociodemographic and clinical characteristics. Descriptive analysis was done for prevalence and binary logistic regression models were used to identify the predictors of anemia. The following variables were assessed as potential predictors: gender, age, residence, educational status, nutritional status, WHO clinical stage, tuberculosis coinfection, ART regimen, and baseline CD4 cell count. Odds ratios (OR) with the 95% confidence intervals were reported and statistical significance was considered at *p*-value <0.05.

Ethical considerations
The study was carried out following approval by the institutional review committee of Wollo University and a subsequent permission from each hospital. Informed consent was waived by the Institutional Review Committee of the University and the hospitals due to the retrospective nature of the study, as all the data were collected from routine medical records. Confidentiality was guaranteed by omitting names or any personal identifiers. In addition, data were kept secured via out the research process to limit accessibility to a third party.

Results
Patient characteristics at enrollment
Medical records of 392 patients (mean age: 35.58 ± 9.46; range: 15–80) years were reviewed. Of the total 392 patients, 218 (55.6%) were females; 200 (51%) were married; 152 (38.8%) completed primary school; 214 (54.6%) were rural dwellers; 130 (33.2%) had a body mass index of <18.5 kg/m²; 62 (15.8%) use social drugs like Khat, alcohol, or cigarette; 59 (15.1%) were tuberculosis coinfected; and 233 (59.4%) of them were on their initial ART regimen.

Clinically, 261 (66.6%) patients were categorized under WHO stage III/IV disease and 134 (34.2%) of them had a baseline CD4 cell count of <100 cells/mm³ with mean cell count of 179
cells/mm$^3$ (range: 2–853). Regarding standard prophylaxis against common opportunistic infections, 354 (90.3%) and 275 (70.2%) of the participants were treated with cotrimoxazole and isoniazid preventive therapies, respectively. The predominant ART regimen was Zidovudine + Lamivudine + Nevirapine and 230 (58.7%) of all participants were on Zidovudine based regimen (Table 1).

**Table 1. Baseline characteristics of patients on HAART in Northeast Ethiopia: 2005–2019.**

| Antiretroviral therapy Regimen | Total |
|--------------------------------|-------|
| AZT/3TC/NVP                    |       |
| AZT/3TC/EFV                    |       |
| TDF/3TC/EFV                    |       |
| TDF/3TC/NVP                    |       |

**Sex**
- Male: 174 (44.4%)
- Female: 218 (55.6%)

**Age; mean: 35.58**
- ≤35 years: 215 (54.8%)
- >35 years: 177 (45.2%)

**Marital Status**
- Never Married: 81 (20.7%)
- Married: 200 (51%)
- Widowed: 43 (11%)
- Divorced: 68 (17.3%)

**Education Level**
- Illiterate: 105 (26.8%)
- Primary school: 152 (38.8%)
- High school: 96 (24.5%)
- College/above: 39 (9.9%)

**Residence**
- Rural: 214 (54.6%)
- Urban: 178 (45.4%)

**Social drug use**
- None: 330 (84.2%)
- Yes: 62 (15.8%)

**Tuberculosis test**
- Negative: 333 (84.9%)
- Positive: 59 (15.1%)

**Experience to ART**
- Naïve: 233 (59.4%)
- Non-naïve: 159 (40.6%)

**WHO Clinical Stage**
- Stage I: 43 (11.6%)
- Stage II: 98 (25.0%)
- Stage III: 223 (56.9%)
- Stage IV: 38 (9.7%)

**CD4 cell count in cells/ml$^3$; (Mean: 179)**
- >200: 130 (33.2%)
- 100–200: 128 (32.7%)
- <100: 134 (34.2%)

**Body Mass Index**
- <18.5 kg/m$^2$: 130 (33.2%)
- 18.5–25 kg/m$^2$: 240 (61.2%)
- >25 kg/m$^2$: 22 (5.6%)

**Cotrimoxazole Prophylaxis**
- No: 38 (9.7%)
- Yes: 354 (90.3%)

**Received Isoniazid**
- No: 117 (29.8%)
- Yes: 275 (70.2%)

**Total**
- 160 (40.8%)
- 70 (17.9%)
- 121 (30.9%)
- 41 (10.5%)

**Abbreviations:** NVP, nevirapine; EFV, efavirenz; AZT, zidovudine; TDF, tenofovir; 3TC, lamivudine;

* were on their initial ART regimen

https://doi.org/10.1371/journal.pone.0265337.t001
Interim treatment outcomes

Of the total 392 study participants, 164 (41.8%) had experienced at least one adverse drug reaction; 326 (83.2%) had good adherence to their prescribed medication; 314 (80.1%) achieved their virologic goal with undetectable viral load and 162 (41.3%) became anemic; of which 11 (6.8%) patients had experienced severe anemia requiring regimen change. The mean duration of follow-up on HAART was 76 ± 32.5 months (range: 7 to 150 months) (Table 2).

Predictors of anemia

Bivariate analysis of sociodemographic and clinical variables revealed that low baseline CD4 cell count (crude odds ratio (COR) 1.66, 95% confidence interval (CI) 1.01–2.74) and TDF based ART regimen (COR 1.69, 95% CI 1.12–2.54) were associated with the risk of anemia. On the other hand, having education level of high school was found to be protective (COR 0.46, 95% CI 0.26–0.83). Similarly, multivariate logistic regression analysis confirmed that baseline CD4 cell count of 100–200 cells/mm³ (adjusted odds ratio (AOR) 1.80, 95% CI 1.05–3.06 and TDF based ART regimen (AOR 2.05, 95% CI 1.31–3.21) were significant predictors of anemia; and being educated was found to be protective (AOR 0.40, 95% CI 0.21–0.78) (Table 3).

Patients with baseline CD4 cell count of 100–200 cells/mm³ were about twice at risk of being anemic compared to those with CD4 cell count of >200 cells/mm³ (AOR 1.80, 95% CI 1.05–3.06). Surprisingly, the risk of experiencing anemia was two times (AOR 2.05, 95% CI 1.31–3.21) among individuals on TDF based ART regimen than those who were on AZT based ART regimen. Patients who were educated up to high school were about 60% less at risk of facing anemia compared to those individuals who didn’t attend school (AOR 0.40, 95% CI 0.21–0.78). However, no statistically significant association was found between anemia and the following covariates: sex, age, residency, body mass index, tuberculosis coinfection, WHO

Table 2. Interim treatment outcome among adults on HAART in Northeast Ethiopia: 2005–2019.

| Antiretroviral therapy Regimen | Total |
|--------------------------------|-------|
| AZT/3TC/NVP | AZT/3TC/EFV | TDF/3TC/EFV | TDF/3TC/NVP |
| Adherence | Good | 131 | 52 | 106 | 37 | 326 (83.2%) |
| | Fair/poor | 29 | 18 | 15 | 4 | 66 (16.8%) |
| Adverse Drug Reaction | No | 89 | 45 | 84 | 10 | 228 (58.2%) |
| | Yes* | 71 | 25 | 37 | 31 | 164 (41.8%) |
| Recent Retroviral Load | Not done | 19 | 6 | 7 | 2 | 34 (8.7%) |
| | Undetectable | 123 | 53 | 99 | 39 | 314 (83.1%) |
| | Detectable** | 18 | 11 | 15 | 0 | 44 (11.2%) |
| New onset Anemia | No | 98 | 49 | 59 | 24 | 230 (58.7%) |
| | Yes | 62 | 21 | 62 | 17 | 162 (41.3%) |
| Duration of follow up in months (mean:76) | <61 | 28 | 12 | 79 | 12 | 131 (33.4%) |
| | 61–90 | 64 | 12 | 30 | 25 | 131 (33.4%) |
| | >90 | 68 | 46 | 12 | 4 | 130 (33.2%) |
| Severity of anemia (n: 162) | Mild | 38 | 10 | 38 | 4 | 90 (55.6%) |
| | Moderate | 23 | 10 | 20 | 8 | 61 (37.6%) |
| | Severe | 1 | 1 | 4 | 5 | 11 (6.8%) |

* Lipodystrophy, anemia, Central Nervous System disturbance, and/or rash,
** >1000 copies/ml

https://doi.org/10.1371/journal.pone.0265337.t002
clinical stage, being naïve or non-naïve to ART, adherence, isoniazid and cotrimoxazole preventive therapies.

### Discussion

In the HAART era, anemia is still common and independently associated with increased mortality. Correction of anemia was associated with reversal of this increased risk. Identification of individuals at risk is crucial for early detection and appropriate management of antiretroviral toxicities like anemia. This study was aimed to investigate the prevalence and associated factors of anemia among adults on highly active antiretroviral therapy.

According to this study, the prevalence of anemia was 41.3% (95% CI: 36–46%) showing that anemia is still prevalent among patients receiving HAART. This finding was comparable with reports from Southern Ethiopia 36.5% [39], Uganda 47.8% [44] and China 39.2% [12]. Our finding was significantly lower than that of prior studies conducted in Uganda 67.4% [45] and Nepal 66.7% [13]. However; this result was higher than reports from different parts of

| Covariates                  | Categories      | Anemia frequency (%) | COR (95% C.I.) | AOR (95% C.I.) |
|-----------------------------|-----------------|----------------------|----------------|----------------|
| Sex                         | Male            | 66 (37.9%)           | 1.00           | 1.00           |
|                             | Female          | 96 (44.0%)           | 1.29 (0.86, 1.93) | 1.22 (0.77, 1.92) |
| Age, mean: 35.58            | ≤35 years       | 93 (43.3%)           | 1.00           | 1.00           |
|                             | >35 years       | 69 (39.0%)           | 0.84 (0.56, 1.26) | 0.77 (0.49, 1.20) |
| Body mass index             | 18.5–25 kg/m<sup>2</sup> | 102 (42.5%)         | 1.00           | 1.00           |
|                             | <18.5 kg/m<sup>2</sup> | 52 (40.0%)          | 0.90 (0.58, 1.39) | 0.88 (0.55, 1.40) |
|                             | >25 kg/m<sup>2</sup> | 8 (36.4%)            | 0.77 (0.31, 1.91) | 0.97 (0.36, 2.59) |
| Residence                   | Urban           | 71 (39.9%)           | 1.00           | 1.00           |
|                             | Rural           | 91 (42.5%)           | 1.12 (0.74, 1.67) | 0.96 (0.60, 1.53) |
| Education Level             | Illiterate      | 52 (49.5%)           | 1.00           | 1.00           |
|                             | Primary school  | 65 (42.8%)           | 0.76 (0.46, 1.26) | 0.71 (0.41, 1.22) |
|                             | High school     | 30 (31.2%)           | 0.46 (0.26, 0.83) | 0.40 (0.21, 0.78) |
|                             | College & above | 15 (38.5%)           | 0.64 (0.30, 1.35) | 0.46 (0.20, 1.07) |
| TB co-infection             | No              | 136 (40.8%)          | 1.00           | 1.00           |
|                             | Yes             | 26 (44.1%)           | 1.14 (0.65, 1.99) | 1.01 (0.54, 1.90) |
| Experience to ART           | Naïve           | 92 (39.5%)           | 1.00           | 1.00           |
|                             | Non-naïve       | 70 (44.0%)           | 1.21 (0.80, 1.81) | 1.08 (0.69, 1.69) |
| Baseline CD4 count          | >200 cells/mm<sup>3</sup> | 46 (35.4%)          | 1.00           | 1.00           |
|                             | 100–200 cells/mm<sup>3</sup> | 61 (47.7%)         | 1.66 (1.01, 2.74) | 1.80 (1.05, 3.06) |
|                             | <100 cells/mm<sup>3</sup> | 55 (41.0%)          | 1.27 (0.77, 2.09) | 1.43 (0.83, 2.47) |
| WHO clinical stage          | Stage I or II   | 52 (39.7%)           | 1.00           | 1.00           |
|                             | Stage III or IV | 110 (42.1%)         | 1.11 (0.72, 1.70) | 1.30 (0.80, 2.10) |
| ART Regimen                 | AZT Based       | 83 (36.1%)           | 1.00           | 1.00           |
|                             | TDF Based       | 79 (48.8%)           | 1.69 (1.12, 2.54) | 2.05 (1.31, 3.21) |
| Adherence                   | Good            | 132 (40.5%)          | 1.00           | 1.00           |
|                             | Fair/Poor       | 30 (45.5%)           | 1.23 (0.72, 2.09) | 1.24 (0.70, 2.19) |
| Isoniazid prophylaxis       | No              | 55 (47.0%)           | 1.39 (0.90, 2.16) | 1.59 (0.98, 2.57) |
|                             | Yes             | 107 (38.9%)          | 1.00           | 1.00           |
| Co-trimoxazole prophylaxis  | No              | 15 (39.5%)           | 1.00           | 1.00           |
|                             | Yes             | 147 (41.5%)          | 1.09 (0.55, 2.16) | 1.18 (0.58, 2.44) |

* Significantly associated with anemia

https://doi.org/10.1371/journal.pone.0265337.t003

PLOS ONE | https://doi.org/10.1371/journal.pone.0265337 | March 25, 2022 | 7 / 11
Ethiopia like Southern Ethiopia 34.8% [17], Addis Ababa 34.6% [16], Northwest Ethiopia 23–34% [21, 40, 46], and a national pooled prevalence of anemia 31.0% [15]. The observed discrepancy might be attributed to the differences in socioeconomic status, health literacy, study design, sample size, inclusion criteria, and most importantly the difference in cut-off values that might be used to define anemia.

Regarding the severity of anemia, majority of cases were mild (55.6%) with the remaining 37.6% to be moderate and only 6.8% of them were severe requiring regimen change. This finding was consistent with a report from rural China where 69.4%, 27.5% and 3.1% of all anemic patients were experiencing mild, moderate and severe anemia, respectively [12]. The prevalence of severe anemia was lower compared to that of previous studies conducted in Southern Ethiopia (21.8%) [17], Addis Ababa (14.5%) [16] and Nepal (17.8%) [13]. However, it was relatively higher than a report form Northwest Ethiopia 2.5% [46].

Multivariate logistic regression analysis shows that TDF based ART regimen and advanced disease (low baseline CD4 cell count) were independent predictors of anemia. Patients with baseline CD4 cells count of 100–200 cells/mm$^3$ were approximately twice more likely to be anemic compared to those individuals with a CD4 count of >200 cells/mm$^3$ (AOR 1.80, 95% CI 1.05–3.06). Similarly, studies conducted in Northwest Ethiopia [21, 40, 41, 46], Nepal [13], Uganda [44], and China [12] showed that low CD4 cell count was significantly associated with anemia. This was also supported by the result of a systematic review and meta-analysis done in Ethiopia [15]. The possible explanation for this association may be opportunistic infections, malnutrition, or HIV associated myelosuppression with advanced disease.

In this study, using Zidovudine (AZT) based ART regimen did not show significant association with anemia despite its frequent association with bone marrow suppression. Unusually, patients who took TDF-based ART regimens were twice more likely to be anemic than those who took AZT-based regimens (AOR 2.05, 95% CI 1.31–3.21). Although a similar finding was reported in Addis Ababa, Ethiopia [18], it is inconsistent with the finding of studies conducted elsewhere in Northwest Ethiopia [21, 40, 41]. Though it needs further investigation, it could be explained by anemia as a complication of TDF induced renal impairment.

This study also identified educational status as predictor of anemia among the study subjects. Patients who never attended school were more likely to suffer from anemia compared to those who completed high school. On the other hand, being educated up to high school was found to be protective (AOR 0.40, 95% CI 0.21–0.78) probably due to good health-seeking behavior or healthy diet patterns. The finding is supported by a report from Northwest Ethiopia [21].

However, no statistically significant association was observed between anemia and the following covariates: sex, age, residency, body mass index, tuberculosis coinfection, WHO clinical stage, being naïve or non-naïve to ART, adherence, as well as isoniazid and cotrimoxazole preventive therapies. These were inconsistent with the findings of previous studies done around the globe [12, 13, 15, 16, 21, 40, 41, 44–46]. Since the causes of anemia in HIV patients are multi-factorial, we recognize the inability of a single study to identify its specific causes exhaustively. Our study was not without limitation. The retrospective nature of this study might be a limitation as the accuracy of data depends on the completeness the records, and hence, information bias might have occurred because of underreporting/missing data elements.

**Conclusions**

In this study, the prevalence of anemia was relatively high though previous studies reported a significant association between HAART and increment in hemoglobin. Low baseline CD4 cell count and TDF based ART regimen were found to be independent predictors of anemia; while
being educated was protective. ART programs should focus on early diagnosis and treatment of HIV as well as routine screening and proper treatment of anemia. Further studies are needed to identify prospectively patients at high risk and design interventions aimed to reduce this risk.

Supporting information
S1 File.
(XLSX)

Acknowledgments
We would like to express our sincere gratitude to the management officials and staff of the hospitals for their cooperation and data collectors for their commitment.

Author Contributions
Conceptualization: Teklehaimanot Fentie Wendie.
Data curation: Teklehaimanot Fentie Wendie, Getnet Mengistu.
Formal analysis: Teklehaimanot Fentie Wendie.
Investigation: Teklehaimanot Fentie Wendie, Getnet Mengistu.
Methodology: Teklehaimanot Fentie Wendie, Getnet Mengistu.
Software: Teklehaimanot Fentie Wendie, Getnet Mengistu.
Writing – original draft: Teklehaimanot Fentie Wendie.
Writing – review & editing: Teklehaimanot Fentie Wendie, Getnet Mengistu.

References
1. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, Ganesan A, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS research and therapy. 2010; 7(14). https://doi.org/10.1186/1742-6405-7-14 PMID: 20507622
2. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Seminars in hematology. 2000; 37(4 Suppl 6):18–23. https://doi.org/10.1016/s0037-1963(00)90064-7 PMID: 11068952
3. Owiredwu WK, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among ghanaiian HAART-naive HIV-patients and those on HAART. African health sciences. 2011; 11(1):2–15. PMID: 21572851
4. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases. 2004; 38(10):1454–63. https://doi.org/10.1086/383031 PMID: 15156485
5. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. The American journal of medicine. 2004; 116(7):27–43. https://doi.org/10.1016/j.amjmed.2003.12.010 PMID: 15050884
6. Abdissa S, Fekade D, Feleke Y, Seboxa T, Diro E. Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital. Ethiopian medical journal. 2012; 50:107–13. PMID: 22924279
7. Larkey M, Asante-Quashie A, Essel A, Kenu E, Ganu V, Neequaye A. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. The Pan African medical journal. 2014; 18.
8. Ferede G, Wondimeneh Y. Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia. BMC Hematol. 2013; 13(1):8. https://doi.org/10.1186/2052-1839-13-8 PMID: 24238076
9. Obirikorang C, Yeboah FA. Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. Journal of biomedical science. 2009; 16(1):1–7. https://doi.org/10.1186/1423-0127-16-102 PMID: 19922646
10. Moore RD, Creagh-Kirk T, Keruly J, Link G, Wang M-C, Richman D, et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Archives of internal medicine. 1991; 151(5):981–6. PMID: 1673837
11. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries. Antiviral therapy. 2006; 13(8):959. PMID: 19195321
12. Jin Y, Li Q, Meng X, Xu Q, Yuan J, Li Z, et al. Prevalence of anaemia among HIV patients in rural China during the HAART era. International journal of STD & AIDS. 2017; 28(1):63–8. https://doi.org/10.1177/0956462415622866 PMID: 26672003
13. Sah SK, Dahal P, Tamang GB, Mandal DK, Shah R, Pun SB. Prevalence and Predictors of Anemia in HIV Infected Persons in Nepal. HIV/AIDS—Research and Palliative Care 2020; 12 193–200.
14. Denue BA, Kida IM, Hammadabo A, Dayar A, Sahabi MA. Prevalence of Anemia and Immunological Markers in HIV-Infected Patients on Highly Active Antiretroviral Therapy in Northeastern Nigeria. Infectious diseases. 2013; 6:25–33. https://doi.org/10.4137/IDRT.S10477 PMID: 24847174
15. Negesse A, Getaneh T, Temesgen H, Taddege T, Abebaw Z. Prevalence of anemia and its associated factors in human immuno deficiency virus infected adult individuals in Ethiopia. A systematic review and meta-analysis. BMC Hematology 2018; 18(32). https://doi.org/10.1186/s12878-018-0127-y PMID: 30459953
16. Gebremedhin KB. Factors Associated with Anemia among People Living with HIV/AIDS Taking ART in Ethiopia. HIV medicine. 2019; 2019:9614205. https://doi.org/10.1155/2019/9614205 PMID: 30941180
17. Zenebe WA, Anbese AT, Tesfaye TS. Anemia And Associated Factors Among Adult People Living With HIV/AIDS Receiving Anti-Retroviral Therapy At Gedeo Zone, SNNPR, Ethiopia. 2018; 11:351–6. https://doi.org/10.2147/HIV.S220461 PMID: 31908543
18. Hassa M, Abegaz WE, Shewame A, Medhin G, Belay M. Prevalence of anaemia and its associated factors in HIV-1 infected patients starting antiretroviral therapy at Zewditu Memorial Hospital, Ethiopia. BMC hematology. 2015; 15(1):6. https://doi.org/10.1186/s12878-015-0024-6 PMID: 26045966
19. Tamir Z, Alemu J, Tsegaye A. Anemia among HIV infected individuals taking art with and without zidovudine at Addis Ababa, Ethiopia. Ethiopian journal of health sciences. 2018; 28(1):73–82. https://doi.org/10.4314/ejhs.v28i1.9 PMID: 29622909
20. Egata G, Dereje B, Desseragen G, Birhanu S. Prevalence of Anemia and associated factors among PHIVs attendants antiretroviral therapy clinics in public health institutions in Dire Dawa town, East Ethiopia. Journal of Medicine, Physiology and Biophysics. 2016; 22.
21. Zenhun KW, Bikis GA, Muhammad EA. Prevalence and associated factors of anemia among adult human immune deficiency virus positive patients on anti-retroviral therapy at Deb ele tabor Hospital, Northwest Ethiopia. BMC research notes. 2019; 12(1):168. https://doi.org/10.1186/s13104-019-4214-3 PMID: 30909968
22. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus—infected patients. The Journal of infectious diseases. 2002; 185(Supplement_2):S110–S4. https://doi.org/10.1086/340198 PMID: 12001031
23. Mocroft A, Kirk O, Barton SE, Dietrich M, Prenoza R, Colebunders R, et al. Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS (London, England). 1999; 13(8):943–50. https://doi.org/10.1097/00002030-199905280-00010 PMID: 10371175
24. Lauer B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005; 39(5):620–5. PMID: 16044017
25. Lundgren JD, Mocroft A. Anemia and survival in human immunodeficiency virus. Clinical infectious diseases. 2003; 37(Supplement_4):S297–S303. https://doi.org/10.1086/376909 PMID: 14581998
26. Akilimali P, Mutombo P, Kayembe P, Kaba D, Mapatano M. Determinants of survival in HIV patients receiving antiretroviral therapy in Goma, Democratic Republic of Congo. Revue d'epidemiologie et de sante publique. 2014; 62(3):201–6. https://doi.org/10.1016/j.respe.2014.03.004 PMID: 24880569
27. Odunukwe N, Idigbe O, Kanki P, Adewole T, Onwujeckwe D, Audu R, et al. Haematological and biochemical response to treatment of HIV-1 infection with a combination of nevirapine+ stavudine+ lamivudine in Lagos Nigeria. Turkish Journal of Haematology. 2005; 22(3):125–31. PMID: 17264834
28. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome.
New England Journal of Medicine. 1990; 323(15):1009–14. https://doi.org/10.1056/NEJM19901011231501 PMID: 1977079

29. Woldeamanuel GG, Wondimu DH. Prevalence of anemia before and after initiation of antiretroviral therapy among HIV infected patients at black lion specialized hospital, Addis Ababa, Ethiopia: a cross-sectional study. BMC hematology. 2018; 18(1):7.

30. Gedefaw L, Yemane T, Sahlemariam Z, Yilma D. Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south west Ethiopia: a comparative study. PloS one. 2013; 8(8):e72202. https://doi.org/10.1371/journal.pone.0072202 PMID: 23977253

31. Curkendall S, Richardson J, Emons M, Fisher A, Everhard F. Incidence of anemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV medicine. 2007; 8(8):483–90. https://doi.org/10.1111/j.1468-1293.2007.00500.x PMID: 17944680

32. Johannesssen A, Naman E, Gundersen SG, Bruun JN. Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC infectious diseases. 2011; 11(1):1–9. https://doi.org/10.1186/1471-2334-11-190 PMID: 21745396

33. Berhane Y, Haile D, Tolessa T. Anemia in HIV/AIDS Patients on Antiretroviral Treatment at Ayder Specialized Hospital, Mekele, Ethiopia: A Case-Control Study. 2020; 11:379–87.

34. Adane A, Desta K, Bezaibih A, Gashaye A, Kassa D. HIV-associated anaemia before and after initiation of antiretroviral therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia. Ethiopian medical journal. 2012; 50(1):13–21. PMID: 22519158

35. Bair BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Current opinion in hematology. 1999; 6(2):89. https://doi.org/10.1097/00062752-199903000-00006 PMID: 10088638

36. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS reviews. 2002; 4(1):13–20. PMID: 11998779

37. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, Disease Group tAASo. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood, The Journal of the American Society of Hematology. 1998; 91(1):301–8. PMID: 9414298

38. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with co-trimoxazole in Côte d’Ivoire. Antiviral therapy. 2005; 10(5):615–24. PMID: 16152755

39. Ageru TA, Koyra MM, Gidebo KD, Abiso TL. Anemia and its associated factors among adult people living with human immunodeficiency virus at Wolaita Sodo University teaching referral hospital. PloS one. 2019; 14(10):e0221853. https://doi.org/10.1371/journal.pone.0221853 PMID: 31596865

40. Melese H, Wassie MM, Woldie H, Tadesse A, Mesfin N. Anemia among adult HIV patients in Ethiopia: a hospital-based cross-sectional study. Journal of translational medicine. 2017; 9:25–30. https://doi.org/10.2147/HIV.S121021 PMID: 28243151

41. Yesuf T, Muhie OA. Prevalence and predictors of anemia among adult HIV infected patients at the University of Gondar Hospital, Northwest Ethiopia. 2019; 11:211–7.

42. Meidani M, Rezaei F, Maracy MR, Avijgan M, Tayeri K. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2012; 17(2):138.

43. Organization WH. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization, 2011.

44. Kyeyune R, Saathoff E, Ezeamama AE, Loscher T, Fawzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014; 14:496. https://doi.org/10.1186/1471-2334-14-496 PMID: 25209550

45. Katembwa C, Muzoora C, Muwanguzi E, Mwambia B, Atuhairwe C, Taremwa IM. Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara Regional Referral Hospital, southwestern Uganda. Journal of blood medicine. 2018; 9:105–10. https://doi.org/10.2147/JBM.S157148 PMID: 29983600

46. Deressa T, Damtie D, Workwine M, Genetu M, Melku M. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: a facility-based cross-sectional study. EJIFCC. 2018; 29(1):36. PMID: 29765285